Concepedia

Resverlogix (Canada)

R(

Statistics

Publications

170

Citations

17.4K

Authors

22

Location

Calgary, Canada

Resverlogix (Canada) is a company institution in Calgary, Canada known for medicine, pharmacology, and cardiovascular disease.

HomepageROR

Top concepts

Publications

170

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection

Richard J. Mills, Sean J. Humphrey, Patrick R.J. Fortuna et al. · Cell · 2021 · 233 citations · Full text

, , +12

RVX-208

Dana Bailey, Ravi Jahagirdar, Allan Gordon et al. · Journal of the American College of Cardiology · 2010 · 229 citations

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist

Kevin G. McLure, Emily M. Gesner, Laura Tsujikawa et al. · PLoS ONE · 2013 · 199 citations · Full text

, , +17

Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease

Stephen J. Nicholls, Allan Gordon, Jan Johansson et al. · Journal of the American College of Cardiology · 2011 · 172 citations

, , +14

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes

Kausik K. Ray, Stephen J. Nicholls, Kevin A. Buhr et al. · JAMA · 2020 · 164 citations · Full text

, , +17

1–5 of 170

Authors

22

  1. JO
    Jan O. Johansson

    Resverlogix (Canada), Canada

    102 publications · 2.1K citations

    25

    h-index

  2. DG
    Dean Gilham

    Resverlogix (Canada), Canada

    79 publications · 2K citations

    22

    h-index

  3. EK
    Ewelina Kulikowski

    Resverlogix (Canada), Canada

    109 publications · 1.9K citations

    22

    h-index

  4. SW
    Sylwia Wasiak

    Resverlogix (Canada), Canada

    80 publications · 5.1K citations

    20

    h-index

  5. MS
    Michael Sweeney

    Resverlogix (Canada), Canada

    67 publications · 1.5K citations

    18

    h-index

1–5 of 22